Morepen Laboratories has secured a multi-year Contract Development and Manufacturing Organisation (CDMO) mandate valued at approximately INR 825 crore (USD 91 million) from a leading global pharma major.

Supplies under the mandate are expected to commence within the next four to five months, with execution scheduled through Q1 of the following financial year, subject to customary operational and regulatory processes.

This engagement marks one of the most significant single CDMO mandates in the company’s history, as it scales its global manufacturing footprint.

Built on over four decades of API manufacturing expertise and regulatory credibility, Morepen’s CDMO platform enables deeper collaboration with global pharmaceutical innovators through structured, multi-year supply programmes.

The mandate reflects the company’s growing capabilities in regulated markets, supported by internationally accredited facilities including USFDA, WHO-GMP and EU approvals. With integrated development-to-commercial manufacturing capabilities, the company is positioned to support complex scale-ups and long-duration supply frameworks.

The company continues to evaluate capacity enhancement and technology investments aligned with its expanding CDMO opportunity pipeline.

Speaking in this regard, Sushil Suri, Chairman and Managing Director, Morepen, said, “This mandate represents an important milestone in the evolution of Morepen’s manufacturing platform. It reflects the confidence global customers place in our quality systems, regulatory track record and execution capabilities. Over the years, we have steadily strengthened our infrastructure and compliance depth, enabling participation in larger, long-duration global programmes.”

He added, “We view CDMO as a natural extension of our established API strengths, creating additional avenues of scale, stability and long-term value creation while continuing to reinforce our core businesses.”